Population
BHK-21 cells and suckling mice
Design
Preclinical
Follow-up
up to 48 h postinfection (in vitro)
Authors
Loading...
siRNA targeting VP1 shows in vivo antiviral activity in mice; leaves open translation to livestock or therapeutic use.
siRNA targeting the VP1 protein of FMDV effectively inhibits viral replication in vitro and in vivo, highlighting its potential as an antiviral therapy.
Chen et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: